https://doi.org/10.4081/reumatismo.2012.321

Anti-cyclic citrullinated peptide antibodies in systemic lupus erythematosus patients with articular involvement: a predictive marker for erosive disease?

Vol. 64 No. 5 (2012)
Submitted: 30 March 2012
Accepted: 14 June 2012
Published: 11 December 2012
Systemic Lupus Erythematosus, anti-cyclic citrullinated peptide antibodies, arthtritis
Abstract Views: 1577
PDF: 1172
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

M. Taraborelli
mara.taraborelli@libero.it
Rheumatology and Clinical Immunology Unit, Spedali Civili and University of Brescia; Rheumatology Chair, University of Pavia., Italy.
F. Inverardi
Rheumatology Chiar, University of Pavia., Italy.
M. Fredi
Rheumatology and Clinical Immunology Unit, Spedali Civili and University of Brescia; Rheumatology Chair, University of Pavia., Italy.
A. Ceribelli
Department of Oral Biology, University of Florida, Gainesville, Florida, United States.
I. Cavazzana
Rheumatology and Clinical Immunology Unit, Spedali Civili and University of Brescia;, Italy.
A. Tincani
Rheumatology and Clinical Immunology Unit, Spedali Civili and University of Brescia;, Italy.
F. Franceschini
Rheumatology and Clinical Immunology Unit, Spedali Civili and University of Brescia;, Italy.
A small number of systemic lupus erythematosus (SLE) patients develop an erosive disease. Some studies have suggested an association between anti-cyclic citrullinated (anti-CCP) antibodies and this pattern of arthritis, but their exact significance in SLE patients remains unclear. The aim of this study was to evaluate the prevalence of anti-CCP antibodies in SLE patients with different subsets of articular disease. Among 521 SLE patients followed in this center from 1976 to 2011, those with articular involvement (n=298) were selected to take part in the study. We searched for anti-CCP2 IgG antibodies in 198 patients using a commercial enzyme linked immunosorbent assay (Immunoscan RA, Eurodiagnostica). In 174 patients the results for rheumatoid factor (RF) by nephelometry were retrospectively collected. C reactive protein (CRP) was obtained from clinical records. Patients were classified into 3 groups: erosive, non-erosive deforming, non-erosive non-deforming arthritis. Results of the different tests were compared among the groups. P<0.05 was considered statistically significant. Anti-CCP antibodies were significantly associated with erosive disease. We also found that RF positivity and increased CRP were more frequent in erosive arthritis and erosive or non-deforming arthritis, respectively, than in non-erosive non-deforming arthritis. This study supports the evidence that anti-CCP antibodies could be a useful marker of erosive disease in SLE patients. Increase in RF and CRP could be an additional means of identifying lupus patients with arthritis at risk of a worse prognosis.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

no
M. Taraborelli, Rheumatology and Clinical Immunology Unit, Spedali Civili and University of Brescia; Rheumatology Chair, University of Pavia.
no
F. Inverardi, Rheumatology Chiar, University of Pavia.
no
M. Fredi, Rheumatology and Clinical Immunology Unit, Spedali Civili and University of Brescia; Rheumatology Chair, University of Pavia.
no
A. Ceribelli, Department of Oral Biology, University of Florida, Gainesville, Florida
no
I. Cavazzana, Rheumatology and Clinical Immunology Unit, Spedali Civili and University of Brescia;
no
A. Tincani, Rheumatology and Clinical Immunology Unit, Spedali Civili and University of Brescia;
no
F. Franceschini, Rheumatology and Clinical Immunology Unit, Spedali Civili and University of Brescia;
no

How to Cite

Taraborelli, M., Inverardi, F., Fredi, M., Ceribelli, A., Cavazzana, I., Tincani, A., & Franceschini, F. (2012). Anti-cyclic citrullinated peptide antibodies in systemic lupus erythematosus patients with articular involvement: a predictive marker for erosive disease?. Reumatismo, 64(5), 321–325. https://doi.org/10.4081/reumatismo.2012.321

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.

Similar Articles

<< < 1 2 3 4 5 6 7 8 9 10 > >> 

You may also start an advanced similarity search for this article.